LILRB2 and central nervous system cancer: Higher expression of LILRB2 indicated shorter DFS and OS both in GBM patients (Fig. 1C) and high-grade glioma patients (Figure S1C), demonstrating that LILRB2 is an oncogene that indicates a dismal prognosis in GBM patients.